IDRx Stock
HealthTechLooking to sell IDRx stock or options?
IDRx specializes in developing oncology-focused precision therapies aimed at transforming cancer treatment. The company creates precision combination therapies, featuring highly selective, engineered drug combinations that target key tumor escape mechanisms to extend therapeutic responses. This approach empowers healthcare professionals to create effective cancer treatments through purposefully crafted combinations, offering tailored cancer medicines for patients.
Investors Include:
Blueprint Medicines, Blackstone, Casdin Capital, RA Capital Management, Rock Springs Capital, Commodore Capital, B-Flexion, Merck, Andreessen Horowitz, Nextech Invest, Borisy Labs, Forge Life Science Partners.